GLP-1 약물 집중 분석: 동향, 요구사항 및 향후 전망

Obesity and diabetes have been two of the greatest public health challenges for decades. Many different diets and fads have promised the public a quick fix and a path to losing excess weight or resolving their diabetic issues. GLP-1 drugs are revolutionizing medicine and the treatment of patients with diabetes, obesity, and other disorders associated with obesity.

With the growing demand of these drugs, pharmaceutical companies, health care providers, telemedicine companies, and pharmaceutical compounders are facing new challenges with GLP-1s. Organizations need to know how to navigate a complex set of issues, including patent considerations, regulatory issues, lawsuits, and M&A activity. 

Foley’s Health Care & Life Sciences and Innovative Technology sectors invite you to join us for a webinar on how your organization can navigate the crossroads of GLP-1s and prepare for this evolving landscape.

This webinar will explore the following GLP-1 topics:

• An inside look on the U.S. Food & Drug Administration’s (FDA) perspective
• How to prepare and secure your patents and safeguard your intellectual property
• The do’s and don’ts of mergers and acquisitions
• Litigation trends
• Clinical trial considerations

Please click here to watch the recording.

CLE

인증 신청서는 캘리포니아주, 캘리포니아주, 플로리다주, 일리노이주, 뉴욕주, 텍사스주, 유타주, 버지니아주 및 워싱턴주에 제출됩니다. 다른 관할권에서 면허를 취득한 참석자에게는 통일된 참석 인증서가 제공되므로 관할권에서 허용하는 경우 직접 신청할 수 있습니다.

Foley & Lardner LLP는 캘리포니아, 콜로라도, 일리노이, 뉴욕, 텍사스 및 유타에서 승인된 MCLE 제공자입니다.
뉴욕 CLE 학점의 경우 이 프로그램은 신규 변호사 및 경력 변호사 모두에게 적합합니다.

참석 인증서는 프로그램 약 8주 후 이메일을 통해 적격 참가자에게 배포될 예정입니다.

­